11 hours ago
1
Sascha Schuermann/Getty Images News
Goldman Sachs has downgraded Baxter International (NYSE:BAX) to Neutral from Buy and trimmed its 12-month price target to $25 from $37 after the healthcare product maker delivered Q2 results that missed Street forecasts on Thursday.
Shares of the Deerfield, Illinois-based firm
English (US) ·